Calculator
    Eligibility

    BMI Eligibility Checker for GLP-1

    Check if your BMI meets the criteria for GLP-1 weight loss medication.

    Published: April 3, 2026-5 min read

    Disclaimer: This tool provides a preliminary check only. Final eligibility is determined by a licensed healthcare provider based on your complete medical history.

    Check Your BMI Eligibility

    GLP-1 Eligibility Criteria

    • BMI 30 or higher: Qualifies for GLP-1 weight loss medication (no comorbidity required)
    • BMI 27-29.9 with comorbidity: Qualifies if you have type 2 diabetes, hypertension, dyslipidemia, sleep apnea, or other weight-related conditions
    • BMI below 27: Does not typically meet standard eligibility criteria for weight loss indication

    Frequently Asked Questions

    What BMI qualifies for GLP-1 medication?

    FDA guidelines indicate GLP-1 weight loss medications for adults with BMI 30+ (obese), or BMI 27+ (overweight) with at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea.

    Is BMI the only factor for eligibility?

    No. While BMI is the primary screening criterion, providers also consider your overall health, medical history, current medications, and contraindications. Some patients with BMI below 27 may benefit from treatment for specific medical conditions like type 2 diabetes.

    What are weight-related comorbidities?

    Common comorbidities that qualify you at BMI 27+ include: type 2 diabetes or prediabetes, high blood pressure, high cholesterol or triglycerides, obstructive sleep apnea, PCOS, fatty liver disease, and osteoarthritis.

    Is BMI an accurate measure of health?

    BMI has limitations: it does not distinguish between muscle and fat, does not account for body composition, and may underestimate or overestimate health risk for certain populations. However, it remains the standard clinical screening tool for GLP-1 eligibility.

    Start Your Consultation

    A Trimi clinician can evaluate your full health picture and determine if GLP-1 treatment is right for you.

    Get Started Today

    More on Calculators & Tools

    GLP-1 Weight Loss Calculator

    Estimate your weight loss.

    GLP-1 Cost Calculator

    Compare treatment costs.

    Which GLP-1 Is Right for You?

    Take the quiz.

    Protein Intake Calculator

    Calculate protein needs.

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the current clinical evidence support for GLP-1-based weight management?

    GLP-1 receptor agonists (semaglutide, tirzepatide) have Phase 3 RCT evidence for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. Trimi offers compounded preparations of the same active ingredients at $99/month (semaglutide) and $125/month (tirzepatide) on the annual plan, prepared per individual prescription by 503A community sterile compounding pharmacies and reviewed by a US-licensed clinician through Beluga Health's 50-state physician network. Compounded preparations are not themselves FDA-approved as drugs; the active ingredients are FDA-approved in the corresponding brand finished products. Eligibility is determined by a licensed clinician.

    Phase 3 RCT evidence base: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SELECT (NEJM 2023), FLOW (NEJM 2024)
    Trimi pricing: $99/month semaglutide / $125/month tirzepatide on annual plan
    Clinical review: Dr. Asad Niazi, MD MPH via Beluga Health 50-state network

    Key Takeaways

    • Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by 503A community sterile compounding pharmacies (VialsRx — Texas State Board pharmacy license #35264 — and GreenwichRx). The active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand finished products (Wegovy / Ozempic and Zepbound / Mounjaro respectively). Compounded preparations are not themselves FDA-approved as drugs.
    • Eligibility for GLP-1 treatment is determined by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Most are mild-to-moderate and concentrated during dose escalation. Severe gastrointestinal symptoms causing dehydration can increase acute kidney injury risk and should be reported to the prescribing clinician.
    • Trimi's clinical review is coordinated by Dr. Asad Niazi, MD MPH through Beluga Health's 50-state physician network. Trimi pricing: $99/month for compounded semaglutide and $125/month for compounded tirzepatide on the annual plan; flat across all prescribed doses within whichever plan, with no enrollment / consultation / shipping fees.
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: October 14, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    — Robyn Lynn CurtisFacebook
    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    — Sarah MillerFacebook
    See all community reviews →

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    2. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    3. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    GLP-1

    Buy Tirzepatide in Texas

    Buy compounded semaglutide online in Texas for $99/month. Learn about Texas telehealth laws, compounding pharmacy access, and how to start affordable GLP-1 weight loss treatment.

    10 minRead More
    Retatrutide

    Retatrutide: Complete Guide

    Detailed comparison of retatrutide vs tirzepatide: 24.2% vs 22.5% weight loss, mechanism differences, side effects, cost projections, and whether to wait or start now.

    10 minRead More
    GLP-1

    Buy Semaglutide in Texas

    Buy compounded tirzepatide online in Texas for $125/month. Dual-action GLP-1/GIP weight loss medication delivered to your door via licensed telehealth.

    10 minRead More
    Cost & Insurance

    LillyDirect Zepbound 2026: $349-$549/mo Vials, Eligibility & Catch

    LillyDirect Zepbound vials cost $349-$549/mo self-pay in 2026 by dose. Eligibility rules, hidden caveats, and how compounded tirzepatide at $125/mo compares.

    10 minRead More

    Start your GLP-1 journey — from $99/mo

    Get Started